Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing

Stefania Napolitano1,2, Aparna R Parikh3, Jason Henry4

  • 1Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.

JCO Precision Oncology
|October 12, 2023
PubMed
Summary

A new statistical model helps clinicians assess the accuracy of circulating tumor DNA (ctDNA) tests for detecting RAS mutations in metastatic colorectal cancer. This tool quantifies the probability of false negatives, improving treatment decisions when RAS mutation status is uncertain.

Related Concept Videos